Dr Reddy's API plant receives USFDA 483 with nine observations

By Dan Stanton contact

- Last updated on GMT

Inside a Dr Reddy's API facility
Inside a Dr Reddy's API facility

Related tags: Dr reddy, Food and drug administration

Dr Reddy’s says an API plant in India is unlikely to be subject to further regulatory enforcement after receiving a US FDA 483 with nine observations.

The Srikakulam facility in the Andhra Pradesh region of India was inspected by the US Food and Drug Administration (FDA) last week resulting in a Form 483 with nine observations, Shilpi Lathia – a company spokesperson – told in-Pharmatechnologist.com

“The observations were largely related to procedural and other compliances of the plant system,”​ she explained. As such “there is no implication on manufacturing and at this stage production continues as normal,”​ she added.

When asked what Dr Reddy’s Laboratories is doing to fix the issues, Lathia told us it is currently responding to the agency with its remediation plans and the firm is “confident it won’t lead to any further enforcement”​ such as a Warning Letter or import alert.

The plant manufactures bulk active pharmaceutical ingredients (APIs) - including bromfenacna, celecoxib, ibuprofen, ketorolac tromethamine, naproxen, naproxen sodium, glimepirid, linagliptin, liraglutide, and nateglinide - used in Dr Reddy’s finished formulated drugs for export to the US and EU.

This is not the first time Dr Reddy’s has fallen foul with the US. In August​ the US Government’s Consumer Product Safety Commission accused the firm of having violated childproof packaging rules, while an inspection of an API plant in Mexico in 2010​ was followed up with an FDA warning letter banning imports from the site.

Continued investment

Originally constructed in 2006 as part of a $100m investment​ in upping its network capacity, the site located in the Devunipalavalasa Special Economic Zone (SEZ) has been joined by a new oral solid dosage manufacturing facility last year.

According to Dr Reddy’s end of year report, the firm has “begun filing some of our new DMFs from this location and [it expects] to file some more during the year ending March 31, 2015.”

It continues: “To meet growing demand in regulated markets, we are in the process of obtaining approvals from the U.S. FDA for products to be manufactured from our recently commissioned oral solid dosage form facility.

“The new plant is intended for the manufacture of new molecules, and certain high volume products of ourGlobal Generics segment.”

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us


View more